The independent platform for news, articles and advice for professionals in laboratory medicine

Re-engineered vancomycin offers hope in fight against antimicrobial resistance

Experts have repeatedly warned that medical science is on the cusp of a ‘post-antibiotic era’, where some infections could become untreatable. Now, scientists in the USA have re-engineered a new version of vancomycin in a bid to wipe out one of the world's most threatening microorganisms. The new antibiotic is designed to be ultra-tough and appears to be a thousand times more potent, according to research published in Proceedings of the National Academy of Science USA.

While the new agent has yet to be tested in animals and humans, It fights bacteria in three different ways, making it much less likely that the microorganisms can develop resistance. The Scripps Research Institute team hope the drug will be ready for use within five years if it proves successful in clinic al trials.

One hard-to-treat infection is vancomycin-resistant enterococci (VRE). It is found in hospitals, can cause dangerous wound and bloodstream infections, and is considered by the World Health Organization (WHO) to be one of the drug-resistant bacteria that poses the greatest threat to human health. Some antibiotics still work against VRE, but the 60-year-old vancomycin is now powerless.

The Scripps team made some strategic modifications to the molecular structure of the old drug to make it more effective in destroying bacterial cell walls. Lead researcher Dr Dale Boger explained: "We made one change to the vancomycin molecule that overcomes current resistance to the agent. Then we added two small changes that built in two additional ways in which it can kill bacteria. So the re-engineered antibiotic has three different mechanisms by which it works, and resistance to such an antibiotic would be very difficult to emerge."

Upcoming Events

ECCMID 2024 - European Congress of Clinical Microbiology and Infectious Diseases

Fira Gran Via, 08038 Barcelona, Spain
27-30 April 2024

British Society for Microbial Technology Annual Microbiology Conference

UK Health Security Agency, Colindale, London
2 May 2024

EQA Reports: Interpreting Key Information & Troubleshooting Tips

ONLINE - Zoom
Thursday 16th May 2024

Participants’ Meeting: UK NEQAS Immunology, Immunochemistry & Allergy

Sheffield Hallam University, City Campus, Howard Street, Sheffield
24th May 2024

Med-Tech Innovation Expo

NEC, Birmingham
5-6 June, 2024

UK NEQAS Blood Coagulation: Clinical and Laboratory Haemostasis 2024

Sheffield Hallam University
5th - 6th June 2024

Access the latest issue of Pathology In Practice on your mobile device together with an archive of back issues.

Download the FREE Pathology In Practice app from your device's App store

Upcoming Events

ECCMID 2024 - European Congress of Clinical Microbiology and Infectious Diseases

Fira Gran Via, 08038 Barcelona, Spain
27-30 April 2024

British Society for Microbial Technology Annual Microbiology Conference

UK Health Security Agency, Colindale, London
2 May 2024

EQA Reports: Interpreting Key Information & Troubleshooting Tips

ONLINE - Zoom
Thursday 16th May 2024

Participants’ Meeting: UK NEQAS Immunology, Immunochemistry & Allergy

Sheffield Hallam University, City Campus, Howard Street, Sheffield
24th May 2024

Med-Tech Innovation Expo

NEC, Birmingham
5-6 June, 2024

UK NEQAS Blood Coagulation: Clinical and Laboratory Haemostasis 2024

Sheffield Hallam University
5th - 6th June 2024

Access the latest issue of Pathology In Practice on your mobile device together with an archive of back issues.

Download the FREE Pathology In Practice app from your device's App store

Step Communications Ltd, Step House, North Farm Road, Tunbridge Wells, Kent TN2 3DR
Tel: 01892 779999
www.step-communications.com
© 2024 Step Communications Ltd. Registered in England. Registration Number 3893025